1. Home
  2. MDGL vs KD Comparison

MDGL vs KD Comparison

Compare MDGL & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • KD
  • Stock Information
  • Founded
  • MDGL 2011
  • KD 2020
  • Country
  • MDGL United States
  • KD United States
  • Employees
  • MDGL N/A
  • KD N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • KD EDP Services
  • Sector
  • MDGL Health Care
  • KD Technology
  • Exchange
  • MDGL Nasdaq
  • KD Nasdaq
  • Market Cap
  • MDGL 6.1B
  • KD 7.0B
  • IPO Year
  • MDGL N/A
  • KD N/A
  • Fundamental
  • Price
  • MDGL $430.70
  • KD $31.88
  • Analyst Decision
  • MDGL Strong Buy
  • KD Strong Buy
  • Analyst Count
  • MDGL 10
  • KD 3
  • Target Price
  • MDGL $474.67
  • KD $46.00
  • AVG Volume (30 Days)
  • MDGL 349.9K
  • KD 2.2M
  • Earning Date
  • MDGL 10-30-2025
  • KD 11-05-2025
  • Dividend Yield
  • MDGL N/A
  • KD N/A
  • EPS Growth
  • MDGL N/A
  • KD N/A
  • EPS
  • MDGL N/A
  • KD 1.23
  • Revenue
  • MDGL $515,547,000.00
  • KD $15,061,000,000.00
  • Revenue This Year
  • MDGL $394.12
  • KD $6.91
  • Revenue Next Year
  • MDGL $57.74
  • KD $2.63
  • P/E Ratio
  • MDGL N/A
  • KD $25.85
  • Revenue Growth
  • MDGL 3421.98
  • KD N/A
  • 52 Week Low
  • MDGL $200.63
  • KD $22.26
  • 52 Week High
  • MDGL $457.16
  • KD $44.20
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 60.99
  • KD 45.42
  • Support Level
  • MDGL $418.36
  • KD $31.15
  • Resistance Level
  • MDGL $440.90
  • KD $33.90
  • Average True Range (ATR)
  • MDGL 12.78
  • KD 0.79
  • MACD
  • MDGL -4.81
  • KD 0.20
  • Stochastic Oscillator
  • MDGL 31.80
  • KD 38.04

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

Share on Social Networks: